Congress will decide whether or not to start contempt proceedings against the CEO of Valeant next week

REUTERS/Christinne MuschiJ. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., speaks during their annual general meeting in Laval, Quebec May 20, 2014.

On Wednesday, members of the Special Committee on Aging will decide whether or not to initiate contempt proceedings against the CEO of Valeant Pharmaceuticals, Michael Pearson.

The move comes after the committee last month issued a Subpoena and Deposition Notice compelling J. Michael Pearson, Chief Executive Officer of Valeant Pharmaceuticals International to personally appear for a deposition on Friday.

Mr. Pearson did not appear at the deposition.

The Committee will meet to consider next steps with respect to Mr. Pearson’s failure to appear.

Here’s some of the text from the notice:

Business Meeting

Special Committee on Aging United States Senate 114^th Congress, 1st Session Hearing/Meeting Schedule

April 8, 2016

Wednesday, April 13, 2016 at 2:00 PM SH-216

Business Meeting to Consider Proceedings Relating to Mr. J. Michael Pearson’s Failure to Appear